TAK-285 is a potent, selective, ATP-competitive, orally active inhibitor of HER2 and EGFR (HER1) used in oncology and kinase research. It exhibits low-nanomolar potency against HER2 and EGFR, shows selectivity over related kinases, and has demonstrated antitumor activity with the ability to cross the blood-brain barrier.
- Potent ATP-competitive inhibitor of HER2 and EGFR with low-nanomolar IC50 values.
- Greater than 10-fold selectivity for HER1/2 compared with HER4.
- Demonstrated antitumor activity and ability to penetrate the blood-brain barrier.
- High purity suitable for biochemical and cellular assays.
- Available as solid packs and as a 10 mM solution in DMSO for stock preparation.
- Well characterized by molecular formula and molecular weight for compound verification.